Sera and lungs metabonomics reveals key metabolites of resveratrol protecting against PAH in rats - 19/12/20
pages | 10 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | This article reveals key metabolites of resveratrol (Rev) protecting against PAH in Rats’ sera and lungs. |
• | This article attempts to determine what the metabolic molecules change and how they change in the development and treatment of PAH by LC–MS-IT-TOF. |
• | We find three key metabolites in the treatment of PAH using Rev. They are hydroxyphenyllactic acid (lung), isopalmitic acid (serum) and cytosine (lung). |
• | Results of the present investigation demonstrates four amino acids pathways are always involved in the treatment of PAH with Rev. |
• | Rev plays a therapeutical role in PAH in rats via amino acids, TCA cycle, choline, linoleic acid and other pathway. |
Abstract |
Pulmonary arterial hypertension (PAH) is a type of high morbidity and mortality disease. Currently, the intrinsic metabolic alteration and potential mechanism of PAH are still not fully uncovered. Previously, we have found that polyphenol resveratrol (Rev) reversed the remodeling of the pulmonary vasculature and decreased the number of mitochondria in pulmonary arterial smooth muscle cells (PASMCs) (Lei Yu et al. (2017)). However, potential effects of Rev on the changed metabolic molecules derived from lung tissue and serum have no fully elucidated. Thus, we conducted a systematic elaboration through the metabonomics method. Various of metabolites in different pathways including amino acid metabolism, tricarboxylic acid cycle (TCA), acetylcholine metabolism, fatty acid metabolism and biosynthesis in male Wistar rats’ sera and lung tissues were explored in three groups (normal group, PAH group, PAH and Rev treatment group). We found that leucine and isoleucine degradation, valine, leucine and isoleucine biosynthesis, tryptophan metabolism and aminoacyl-tRNA biosynthesis were involved in the development of PAH. Hydroxyphenyllactic, isopalmitic acid and cytosine might be significant key metabolites. Further work in this area may inform personalized treatment approaches in clinical practice of PAH through elucidating pathophysiology mechanisms of experimental verification.
Le texte complet de cet article est disponible en PDF.Keywords : Resveratrol (Rev), Pulmonary arterial hypertension (PAH), Lung, Serum, Metabolites
Plan
Vol 133
Article 110910- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?